News

The study will enroll an estimated 1,000 patients, of whom approximately 200 will have vitiligo. The remaining participants will be at-risk family members, some 40 to 60 of whom are expected to develop vitiligo during the 5-year study.

The FDA has cleared several new products this week, including the first monoclonal antibody for RSV in infants, a novel therapy for newly diagnosed patients with AML and a postexposure anthrax vaccine. Additionally, an FDA decision on donanemab for Alzheimer’s is expected by the end of this year.

Professional development should take steps to incorporate outreach into medical school curriculums, say Rosemay Michel, D.P.M., and Gary M. Rothenberg, D.P.M. "Students must learn what motivates people to make healthy choices in their daily lives, including the influences of schools, faith-based groups, social media and extended family on personal decision-making," argue Michel and Rothenberg.

Chronic insomnia has been linked to a variety of mental and physical illnesses. Researchers have found that cognitive behavioral therapy is often effective.

In a study recently published in the JAMA Network, researchers sought to investigate the use of patient-facing digital health technologies for opioid use disorder (OUD) by organizations in the United States with ACO contracts. The search began as it was unclear whether these technologies serve as substitute or complements to traditional SUD treatment resources in health care organizations.

Emissions from healthcare facilities contribute to climate change, and climate change, in turn, is presenting new challenges for healthcare.

Bryant Hoyal, VP of Client Services, Strategic Accounts at Relatient suggests filling appointment schedules with patients based on their specific needs through best practices is an efficient way to drive revenue, as well as balance workflows for staff. Outside of scheduling tools, Hoyal stressed the importance of being a data-driven organization to understand and control the workflow of your practice.

Approvals this week include Opill, the first nonprescription oral contraceptive, the use of Veklury for COVID-19 in patients with severe renal impairment, and the earlier use of Leqvio for in heart disease. In addition, Takeda pulled its application for a dengue vaccine.

This week, the FDA granted full approval to the Alzheimer’s drug Leqembi, set an action for review of zolbetuximab to treat gastric cancers and rejected Amneal’s new drug application (NDA) Parkinson’s disease treatment.

In this population-based cohort study, researchers compared the risks of incident cardiovascular, neurological, and mental health conditions and rheumatoid arthritis in a year following COVID hospitalization to three different groups: pre-pandemic hospitalization for influenza, pre-pandemic hospitalization for sepsis and hospitalization for sepsis post-pandemic.